6533b872fe1ef96bd12d2fca

RESEARCH PRODUCT

Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis

C.f AnsevinA Müller-jenssenDieter PongratzHans-hilmar GoebelWolfgang Müller-felberKenneth RickerM Töpfer

subject

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineGastroenterologyMuscular DiseasesPhysical StimulationInternal medicineAzathioprineMyasthenia GravismedicineHumansGenetics (clinical)AsthmaAcetylcholine receptorbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPyridostigmineRipplingPediatrics Perinatology and Child HealthImmunologyNeurology (clinical)medicine.symptombusinessImmunosuppressive AgentsMuscle ContractionPyridostigmine BromideMuscle contractionmedicine.drug

description

Rippling muscle disease is a rare autosomal dominant disorder that may occur sporadically. In this report two patients presenting with rippling muscles followed by myasthenia gravis are described. Our first patient developed rippling muscles about 1 month after infection with Yersinia enterocolitica. Two years later myasthenia gravis appeared. Our second patient had a 2-year history of asthma prior to the onset of rippling muscles which preceded the myasthenic symptoms by 4-8 weeks. Acetylcholine receptor and anti-skeletal muscle antibody titers were positive in both patients. In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.

https://doi.org/10.1016/s0960-8966(99)00065-6